Extra‐thymically induced T regulatory cell subsets: the optimal target for antigen‐specific immunotherapy. Issue 2 (June 2015)

• Record Type: Journal Article
• Authors: Verhagen, Johan; Wegner, Anja; Wraith, David C.
• Is Part Of: Immunology. Volume 145:Issue 2(2015:Jun.)
• Page Start: 171
• Page End: 181
• Publication Date: 2015-06
• Subjects: Immunology -- Periodicals
• DOI: 10.1111/imm.12458
• Languages: English
• ISSNs: 0019-2805

Abstract

<abstract abstract-type="main" id="imm12458-abs-0001"> <title>Summary</title> <p>Antigen‐specific immunotherapy aims to selectively restore tolerance to innocuous antigens in cases of autoimmune or allergic disease, without the need for general immune suppression. Although the principle of antigen‐specific immunotherapy was discovered more than a century ago, its clinical application to date is limited, particularly in the control of autoimmunity. This has resulted mainly from a lack of in‐depth understanding of the underlying mechanism. More recently, the differentiation of extra‐thymically induced T regulatory (Treg) cell subsets has been shown to be instrumental in peripheral tolerance induction. Two main types of inducible Treg cells, interleukin‐10‐secreting or Foxp3⁺, have now been described, each with distinct characteristics and methods of therapeutic induction. It is crucial, therefore, to identify the suitability of either subset in the control of specific immune disorders. This review explores their natural function, the known mechanisms of therapeutic differentiation of either subset as well as their <italic>in vivo</italic> functionality and discusses new developments that may aid their use in antigen‐specific immunotherapy, with a focus on autoimmune disease.</p> </abstract>